For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
33
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      155
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. The main goal of the treatment of HCV infection is to eliminate the virus from the body, which in turn leads to stopping the progression or causes the regression of previously formed changes in the liver. The current version of the guidelines prioritizes pangenotypic regimens and includes guidelines for special patient populations such as children, patients with cirrhosis, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection, patients with renal failure, liver failure and lack of response to previous therapies as well as patients in the peri-transplant period.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          EASL recommendations on treatment of hepatitis C: Final update of the series☆

          Jean-Michel Pawlotsky, Francesco Negro, Alessio Aghemo … (2020)
          Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
          Article 0 comments Cited 300 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

            (2016)
            Sustained virological response following interferon-based antiviral treatment of chronic hepatitis C is associated with decreased long-term risk of hepatocellular carcinoma (HCC) in advanced liver fibrosis. An unexpected high rate of HCC recurrence following antiviral treatment using direct-acting antiviral (DAA) has recently been reported.
            Article 0 comments Cited 127 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

              Sarah Blach, Norah Terrault, Frank Tacke … (2022)
              Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends.
              Article 0 comments Cited 114 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Clin Exp Hepatol
                Journal ID (iso-abbrev): Clin Exp Hepatol
                Journal ID (publisher-id): CEH
                Title: Clinical and Experimental Hepatology
                Publisher: Termedia Publishing House
                ISSN (Print): 2392-1099
                ISSN (Electronic): 2449-8238
                Publication date (Electronic): 24 March 2023
                Publication date (Print): March 2023
                Volume: 9
                Issue: 1
                Pages: 1-8
                Affiliations
                [1 ]Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland
                [2 ]Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
                [3 ]Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland
                [4 ]Department of General, Transplantation and Liver Surgery, Medical University of Warsaw, Warsaw, Poland
                [5 ]Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
                [6 ]Department of Infectious Diseases and Hepatology, Medical University of Łódz, Łódź, Poland
                [7 ]Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland
                [8 ]Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
                Author notes
                Address for correspondence: Prof. Robert Flisiak, Department of Infectious Diseases and Hepatology, Medical University of Białystok, 14 Żurawia St., 15-540 Bialystok, Poland, e-mail: robert.flisiak1@ 123456gmail.com
                Article
                Publisher ID: 50360
                DOI: 10.5114/ceh.2023.125957
                PMC ID: 10090994
                PubMed ID: 37064834
                SO-VID: 93a22e35-c96f-44f9-a5e2-34e9f72ac292
                Copyright © Copyright © 2023 Clinical and Experimental Hepatology
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License ( http://creativecommons.org/licenses/by-nc-sa/4.0/)

                History
                Date received : 07 February 2023
                Date accepted : 07 February 2023
                Categories
                Subject: Review Paper

                Keywords: therapy,liver,hcv,recommendations,viral hepatitis
                Data availability:
                Keywords: therapy, liver, hcv, recommendations, viral hepatitis

                Comments

                Comment on this article

                scite_

                Similar content155

                See all similar

                Cited by2

                See all cited by

                Most referenced authors638

                See all reference authors